** Shares of drugmaker Sage Therapeutics SAGE.O rise 36.4% to $7.57 premarket
** Drugmaker Biogen BIIB.O will buy all outstanding shares of Sage that it does not already own for $7.22 apiece, a filing showed on Friday
** The offer price, representing a 30% premium to stock's close on Friday, values Sage's equity at $441.7 mln, according to Reuters calculations
** Brokerage William Blair says the offer is prudent to maximize potential for Sage and Biogen's depression drug, Zurzuvae, without materially impacting Biogen's M&A deal capacity
** Up to last close, stock down 78.1% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。